Inactive Instrument

Highlights Fresh Start Private Management Inc Other OTC

Equities

US35804J1025

End-of-day quote Other OTC Other stock markets
- ^USD	-

15/05	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	BioCorRx Inc. Announces Board Resignations	CI

Highlights

BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/23/15	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
BioCorRx Inc. Announces Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial At 4Th Annual NIH HEAL Initiative Investigator Meeting	08/23/08	CI
BioCorRx Inc. Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder, Which is Being Developed Under BioCorRx Pharmaceuticals, Inc	19/23/19	CI
BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States	07/22/07	CI
BioCorRx Inc. agreed to Spin-Off BioCorRx Pharmaceuticals, Inc.	22/22/22	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
BioCorRx Inc. Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104	13/22/13	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI
BioCorRx Inc. Announces First Subject Dosed in Phase I Clinical Trial of Bicx104	30/22/30	CI
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/22/31	CI
BioCorRx Receives IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder	16/22/16	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
BioCorRx Inc. Files Patent Application with the Russian Patent Office for Naltrexone Implant	07/21/07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fresh Start Private Management Inc Other OTC

Equities

US35804J1025

Highlights

Filters